Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Genmab A/S (GMAB)

Genmab A/S (GMAB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,446,944
  • Shares Outstanding, K 652,801
  • Annual Sales, $ 804,360 K
  • Annual Income, $ 324,680 K
  • 60-Month Beta N/A
  • Price/Sales 24.98
  • Price/Cash Flow 57.97
  • Price/Book 9.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate 0.02
  • Number of Estimates 4
  • High Estimate 0.06
  • Low Estimate 0.00
  • Prior Year 0.20
  • Growth Rate Est. (year over year) -90.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.13 +20.68%
on 05/04/20
31.30 -6.96%
on 05/28/20
+4.12 (+16.48%)
since 05/01/20
3-Month
16.24 +79.31%
on 03/16/20
31.30 -6.96%
on 05/28/20
+5.91 (+25.46%)
since 03/03/20
52-Week
16.24 +79.31%
on 03/16/20
31.30 -6.96%
on 05/28/20
+11.61 (+66.30%)
since 06/03/19

Most Recent Stories

More News
Genmab's Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Genmab.

GMAB : 29.23 (-1.88%)
ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region

IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced...

IPATF : 1.1000 (+2.38%)
IPA.VN : 1.480 (+2.07%)
GMAB : 29.23 (-1.88%)
MRUS : 14.85 (+2.13%)
Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics

Company Announcement

GMAB : 29.23 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade GMAB with:

Business Summary

Genmab A/S is a biotechnology company. It specializes in development of antibody therapeutics for the treatment of cancer. The company's product pipeline includes DARZALEX(R), Arzerra(R), tisotumab vedotin, enapotamab vedotin, HexaBody-DR5/DR5(R) and DuoBody-CD3xCD20 (R),which are in clinical stage....

See More

Key Turning Points

2nd Resistance Point 30.35
1st Resistance Point 30.07
Last Price 29.23
1st Support Level 29.53
2nd Support Level 29.27

See More

52-Week High 31.30
Last Price 29.23
Fibonacci 61.8% 25.55
Fibonacci 50% 23.77
Fibonacci 38.2% 21.99
52-Week Low 16.24

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar